Experimental Justification of Approaches to Developing Pathogenetic Means towards the Prevention and Treatment of Early Postradiation Gastrointestinal Disorders

• Published in: Biology bulletin of the Russian Academy of Sciences Vol. 46; no. 11; pp. 1571 - 1575
• Main Authors: Drachev, I. S., Legeza, V. I., Seleznev, A. B., Grebenyuk, A. N.
• Format: Journal Article
• Language: English
• Published: Moscow Pleiades Publishing 01-12-2019; Springer Nature B.V
• Subjects: Biochemistry; Biomedical and Life Sciences; Cell Biology; Cimetidine; Clinical trials; Diarrhea; Drug development; Ecology; Gastrointestinal diseases; Indomethacin; Life Sciences; Metoclopramide; Modification of Radiation Effects; Naloxone; Radiation; Serotonin S3 receptors; Vomiting; Zoology; antidiarrheal agents; primary reaction to irradiation; gastrointestinal syndrome; diarrhea; ionizing radiation; irradiation; nausea; vomiting; antiemetics
• ISSN: 1062-3590; 1608-3059
• DOI: 10.1134/S1062359019110116

Experiments on dogs have shown that antagonists of receptor types D
2
(domperidone, metoclopramide, dimethpramide), 5-HT
3
(ondansetron, palonosetron), and NK
1
(aprepitant) impair gastrointestinal manifestations of the primary reaction to irradiation (vomiting and diarrhea). Blockers of H
2
(cimetidine) and opiate (naloxone) receptors, inhibitors of prostaglandin synthesis (voltaren, indomethacin), and M-cholinolytic methacin have a predominantly antidiarrheal effect. None of the drugs in our trials reduced the severity of early postradiation hypokinesia. The most promising avenue to effectively prevent and treat the main clinical manifestations of the primary reaction to irradiation is assumed to be the development of complex drugs that affect various aspects of pathogenesis.